Autolus Therapeutics reported a 95% year-over-year increase in Q3 2026 net product revenue for AUCATZYL, reaching $41.2 million. The company now expects full-year 2026 AUCATZYL revenue to meet or exceed the upper end of $150 million, driven by expanding demand and manufacturing efficiencies. Clinical trials for obe-cel in pediatric leukemia, lupus nephritis, and multiple sclerosis continue progressing, with key data presentations planned through 2028. Autolus also improved its gross margin to 57% and expects sufficient cash to fund operations into Q2 2028.
Autolus Therapeutics' Q3 2026 financial results and business updates provide context for readers following health-sector stocks. As of Nov 10, 2026 17:51 WIB, among 150 priced US health-sector stocks tradable on Pluang, 76 rose and 58 fell. Notable movers include TVTX at USD 50.50 with a 1-day change of -2.19%, ABEO at USD 2.59 with a 1-day change of +1.97% and Pluang order activity showing 29% Sell / 71% Buy, and HIMS at USD 22.54 with a 1-day change of -1.77% and 100% Buy order activity. The most notable figure is ABEO's 71% buy order activity on Pluang.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
